MedTrace Logo

Assessment of PD-1 and PD-L1Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study

NCT04892381 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2021-05-19

No results posted yet for this study

Summary

Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study

Conditions

  • Lichen Planus

Interventions

DIAGNOSTIC_TEST

Skin Biopsy

* Skin biopsy will be taken under local anesthesia : * From each normal control; a 3 mm punch skin biopsy from a sun protected area will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study. * From each LP patient; two punch skin biopsies will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study: i. The first biopsy will be a 3 mm punch biopsy from the center of LP lesional skin of sun protected area ii. The second biopsy will be a 3 mm punch biopsy from non lesional skin at least 15 cm away from the edge of any existing LP lesion of sun protected area * The level of PD1 and PD-L1 will be detected using ELISA technique. * The lesional biopsy will be assessed by routine hematoxylin and eosin (H\&E) to confirm the diagnosis of LP

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Rana A Misaad · Cairo University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-18
Primary Completion
2022-04-18
Completion
2022-04-22

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04892381 on ClinicalTrials.gov